Guo Chun-Bao, Wang Shan, Deng Chun, Zhang Dian-Liang, Wang Fu-Ling, Jin Xian-Qing
Laboratory of Surgery, Children's Hospital of Chongqing Medical University, Chongqing, Peoples Republic of China.
Mol Diagn Ther. 2007;11(3):183-92. doi: 10.1007/BF03256240.
Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was designed to investigate the significance of MMP2 and MMP9 in lung cancer tissue or serum, and their correlation with lung cancer prognosis.
Immunohistochemical analysis was performed to determine MMP2 and MMP9 staining in human nonsmall cell lung cancer (NSCLC). Serum MMP2 and MMP9 protein levels in patients after surgery were measured using the ELISA method. The correlation between MMP2 and MMP9 serum levels and clinicopathological features of NSCLC were analyzed by survival analysis. We also performed reverse transcriptase (RT)-PCR assays to detect messenger RNA (mRNA) expression to further confirm the activity of MMP2 and MMP9 in human lung cancer.
Increased MMP2 immunostaining and MMP2 serum level correlated with advanced tumor stage and the presence of distant metastasis (Pearson's chi(2) test and ANOVA, p < 0.05). However, for MMP9, only serum level showed a correlation with advanced tumor stage. No significant correlation was observed between MMP2 or MMP9 immunostaining expression and tumor histologic features (Pearson's chi(2) test, p = 0.061 and p = 0.087, respectively). A high densitometry value of MMP2 and MMP9 PCR products (i.e. mRNA expression level) was related to poor differentiation grade, distant metastasis, and small cell carcinoma histologic type (ANOVA, p < 0.05).
Our results suggest that MMP2 is a more sensitive predictor than MMP9 of lung cancer progression, metastasis, and survival. Serum MMP2 levels may be a valuable prognosis variable and could help to stratify lung cancer patients into low- and high-risk groups.
基质金属蛋白酶(MMPs)在癌症发展的多个步骤中发挥重要作用。MMP2和MMP9先前已被认为与肺癌的淋巴和血管侵袭有关;然而,MMP2和MMP9的表达及预后意义尚未完全阐明。本研究旨在探讨MMP2和MMP9在肺癌组织或血清中的意义,以及它们与肺癌预后的相关性。
采用免疫组织化学分析来确定人非小细胞肺癌(NSCLC)中MMP2和MMP9的染色情况。采用酶联免疫吸附测定(ELISA)法测量术后患者血清中MMP2和MMP9蛋白水平。通过生存分析来分析MMP2和MMP9血清水平与NSCLC临床病理特征之间的相关性。我们还进行了逆转录酶(RT)-聚合酶链反应(PCR)检测以检测信使核糖核酸(mRNA)表达,从而进一步证实MMP2和MMP9在人肺癌中的活性。
MMP2免疫染色增强及MMP2血清水平升高与肿瘤晚期及远处转移的存在相关(Pearson卡方检验和方差分析,p<0.05)。然而,对于MMP9,只有血清水平与肿瘤晚期相关。MMP2或MMP9免疫染色表达与肿瘤组织学特征之间未观察到显著相关性(Pearson卡方检验,p分别为0.061和0.087)。MMP2和MMP9聚合酶链反应产物的高光密度值(即mRNA表达水平)与低分化程度、远处转移及小细胞癌组织学类型相关(方差分析,p<0.05)。
我们的结果表明,在肺癌进展、转移及生存方面,MMP2是比MMP9更敏感的预测指标。血清MMP2水平可能是一个有价值的预后变量,有助于将肺癌患者分为低风险和高风险组。